内部人交易雷达

美国 · SEC Form 4 · 快照日期： 2026-10-18 · 构建时间： 2026-10-18 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

MARIMED INC.

MRMD · OTC · CIK 0001522767 · Healthcare · Drug Manufacturers—Specialty & Generic

内部人信号

32.2 / 100

1 位买方 · 4 条买入交易行 · $7.8K 买入总额

为什么有这个信号？

买方广度较低
买入规模较低
角色中等
近期性较低
确信度较强
评分构成

每条进度条表示其对当前分数的贡献；权重和公式保持不变。

Cluster+7.0 / 35
买入规模+1.3 / 25
角色+13.0 / 20
近期性+0.8 / 10
确信度+10.0 / 10

哪些因素限制了当前分数？

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ 角色得分低 · 买入者中职位最高的是：President and CEO（CEO、董事长和持股 10% 以上的股东得分最低）
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct
Crandall RyanChief Commercial Officer
○○○○○○○○○○
Shaw TimothyChief Operating Officer
○○○○○○○○○○
Levine Jon RPresident and CEO
○○○○○○○
Pinho MarioChief Financial Officer
○○○○
Selhub Eva M.D.Director
○○
Gildea Edward JDirector
○○
● 买入▼ 卖出○ 其他

Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.

买方广度与集中度

合资格买方1
买入集中度100%最大买方： Levine Jon R · $7.8K
聚集买入 · 15天1 insider峰值活动： 2026-05-20–2026-05-22

Roles in the peak window: President and CEO. Concentration uses priced qualifying P lines only and does not change the saved score.

信号历史

32.2 / 100

最新留档分数

→ +0.0 pts相对上一个留档快照
  1. 32.2
  2. 32.2
  3. 32.2
  4. 32.2
  5. 32.2

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

近期 Form 4 活动

5买入
0卖出
85其他 Form 4 交易行
49SEC 申报 · 365天
买入4 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他42 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M
-21.2%
3M
-4.5%
6M
-10.0%
12M
-60.4%

波动率与流动性

波动率
95.5%
Beta
—
平均每日成交额
USD 33,169

估值

市值
USD 25.4M
P/E
—

基本面

利润率
-9.1%
ROE
-29.0%
细分行业
Drug Manufacturers—Specialty & Generic

市场数据

价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, 利润率, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-10 · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数
1,000
上期报告
44,669
日均成交量
1,661,239
回补天数
≤ 1.0

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2026-05-22Levine Jon R买入 (P)Common stock60,000USD 0.08USD 4,600SEC 申报 ↗
2026-05-20Levine Jon R买入 (P)Common stock40,000USD 0.08USD 3,200SEC 申报 ↗
2025-12-12Shaw Timothy买入 (P)Common stock45,455USD 0.11USD 5,000SEC 申报 ↗

Form 4 申报证据

90 transaction lines in the latest 365-day window; 194 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-10-15Shaw Timothy期权行权／转换 (M)Common stock42,657USD 0.00USD 0SEC 申报 ↗
2026-10-15Shaw Timothy代扣税 (F)Common stock12,520USD 0.06USD 751SEC 申报 ↗
2026-10-15Pinho Mario期权行权／转换 (M)Common stock38,282USD 0.00USD 0SEC 申报 ↗
展开近期 Form 4 证据 (30 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-10-15Shaw Timothy期权行权／转换 (M)Common stock42,657USD 0.00USD 0SEC 申报 ↗
2026-10-15Shaw Timothy代扣税 (F)Common stock12,520USD 0.06USD 751SEC 申报 ↗
2026-10-15Pinho Mario期权行权／转换 (M)Common stock38,282USD 0.00USD 0SEC 申报 ↗
2026-10-15Pinho Mario代扣税 (F)Common stock11,236USD 0.06USD 674SEC 申报 ↗
2026-10-15Levine Jon R期权行权／转换 (M)Common stock30,625USD 0.00USD 0SEC 申报 ↗
2026-10-15Levine Jon R代扣税 (F)Common stock8,989USD 0.06USD 539SEC 申报 ↗
2026-10-15Crandall Ryan期权行权／转换 (M)Common stock32,812USD 0.00USD 0SEC 申报 ↗
2026-10-15Crandall Ryan代扣税 (F)Common stock9,631USD 0.06USD 578SEC 申报 ↗
2026-10-02Shaw Timothy期权行权／转换 (M)Common stock9,981USD 0.00USD 0SEC 申报 ↗
2026-10-02Shaw Timothy代扣税 (F)Common stock3,459USD 0.07USD 241SEC 申报 ↗
2026-10-02Levine Jon R期权行权／转换 (M)Common stock11,517USD 0.00USD 0SEC 申报 ↗
2026-10-02Levine Jon R代扣税 (F)Common stock3,991USD 0.07USD 278SEC 申报 ↗
2026-09-28Crandall Ryan期权行权／转换 (M)Common stock6,046USD 0.00USD 0SEC 申报 ↗
2026-09-28Crandall Ryan代扣税 (F)Common stock2,095USD 0.08USD 168SEC 申报 ↗
2026-09-01Shaw Timothy期权行权／转换 (M)Common stock65,000USD 0.00USD 0SEC 申报 ↗
2026-09-01Shaw Timothy代扣税 (F)Common stock22,523USD 0.08USD 1,802SEC 申报 ↗
2026-07-15Shaw Timothy期权行权／转换 (M)Common stock42,656USD 0.00USD 0SEC 申报 ↗
2026-07-15Shaw Timothy代扣税 (F)Common stock14,781USD 0.07USD 1,035SEC 申报 ↗
2026-07-15Selhub Eva M.D.期权行权／转换 (M)Common stock173,077USD 0.00USD 0SEC 申报 ↗
2026-07-15Pinho Mario期权行权／转换 (M)Common stock88,276USD 0.00USD 0SEC 申报 ↗
2026-07-15Pinho Mario代扣税 (F)Common stock30,589USD 0.07USD 2,141SEC 申报 ↗
2026-07-15Levine Jon R期权行权／转换 (M)Common stock30,625USD 0.00USD 0SEC 申报 ↗
2026-07-15Levine Jon R代扣税 (F)Common stock10,612USD 0.07USD 743SEC 申报 ↗
2026-07-15Gildea Edward J期权行权／转换 (M)Common stock192,308USD 0.00USD 0SEC 申报 ↗
2026-07-15Crandall Ryan期权行权／转换 (M)Common stock32,813USD 0.00USD 0SEC 申报 ↗
2026-07-15Crandall Ryan代扣税 (F)Common stock11,370USD 0.07USD 796SEC 申报 ↗
2026-07-15Allen David R期权行权／转换 (M)Common stock192,308USD 0.00USD 0SEC 申报 ↗
2026-06-15Crandall Ryan期权行权／转换 (M)Common stock250,000USD 0.00USD 0SEC 申报 ↗
2026-06-15Crandall Ryan代扣税 (F)Common stock86,626USD 0.07USD 6,064SEC 申报 ↗
2026-06-12Selhub Eva M.D.期权行权／转换 (M)Common stock75,000USD 0.00USD 0SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-18
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码MRMD
CIK0001522767
行业Healthcare
细分行业Drug Manufacturers—Specialty & Generic Yahoo Finance
SEC SIC2833 Medicinal Chemicals & Botanical Products
交易所OTC

数据覆盖

本地 Form 4 历史194 transaction lines from 2020-11-17 to 2026-10-15
5 P purchase lines · 8 S sale lines · 181 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.